Sustained-Release Medication Technology Reviewed
Ophthalmologists and their patients with glaucoma would welcome an implant that delivers medication when needed. Jason Bacharach, MD, founding partner and medical director, North Bay Eye Associates in Sonoma County, CA, recently addressed this possibility. He said an implant that offers sustained-release medication can be viewed as “ancillary treatment” where medicine is still delivered via a MIGS-type device that is eventually replaced. Dr Bacharach likened the emerging technology to coated stents used in cardiology.
He and his colleagues reviewed the devices that are getting closer to use in practice and examined the stumbling blocks that remain.
You can read more here.
Lipner M, Farid M. Examining the sustained front. [Published online May 2018]. Eye World.
